Ipamorelin Research

Raun K, Hansen BS, Johansen NL, et al.

The landmark study establishing Ipamorelin as the first growth hormone secretagogue with high selectivity for GH release — meaning it stimulates GH without significantly raising cortisol, prolactin, or ACTH. The study demonstrated that Ipamorelin produced robust GH release in rats comparable to GHRP-6 and hexarelin, but with approximately 90% less cortisol response and no meaningful ACTH elevation. This selectivity profile is what distinguishes Ipamorelin from older GHRPs and makes it the preferred GHRP for stacking with GHRH analogs like CJC-1295. This paper is the foundation of Ipamorelin’s reputation as the “cleanest” growth hormone secretagogue.

Hansen BS, et al.

A 12-week study examining Ipamorelin’s effects on body composition and bone health in aged rats — directly relevant to its research application in age-related metabolic decline. Findings included significant increases in bone mineral content, reduced adiposity, and increased lean mass, all attributed to sustained GH/IGF-1 axis activation. This study expanded Ipamorelin’s research profile beyond simply stimulating GH release to demonstrating tangible downstream effects on body composition — establishing the biological rationale for its use in anti-aging and body recomposition research.

Gobburu JVS, et al.

One of the few human pharmacokinetic studies of Ipamorelin, characterizing how it behaves in the human body. The study modeled the relationship between Ipamorelin plasma concentrations and GH release kinetics in healthy volunteers — confirming that the dose-response relationship seen in animal models translates to humans. The paper established Ipamorelin’s approximate half-life and the timing of its GH release peak, which informs research dosing protocols. This is a foundational reference for understanding Ipamorelin’s human pharmacology.

Sigalos JT, Pastuszak AW

A clinical review examining Ipamorelin alongside other GH secretagogues for applications in metabolic syndrome and hypogonadism. The paper summarizes Ipamorelin’s selectivity advantage over GHRP-2 and GHRP-6 and reviews its potential role as an adjunct to testosterone therapy for improving body composition in hypogonadal males. It also covers the synergistic GH response when Ipamorelin is combined with GHRH analogs — documenting 2–4x greater GH AUC compared to either compound in isolation. A useful clinical context paper for understanding where Ipamorelin fits in therapeutic applications.